Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: lazar921 who wrote (19405)	3/10/1999 11:01:00 PM
From: QuietWon	Read Replies (1) \| Respond to of 122087

why is that good for the longs?? if no shares to short, it has one & only direction to go - up!

To: lazar921 who wrote (19405)	3/10/1999 11:06:00 PM
From: QuietWon	Read Replies (2) \| Respond to of 122087

IMCL - another way of looking at it- if Genetech able to earn $30 million in first 3 months, did they keep up that pace or was that just ramping up? Suppose it's flat $30 million revs for at least 4 3-months periods ie. $120 million in the first 12 months the drug is offered. 120/25 total shares about $5 per share in revenue in the first 12 months. Now what is the net margin as % sales - say 25% giving $1.25 per share in earnings oh oh earnings isn't that bad. So based on the above $1.25 EPS from C225 alone on a best guess estimate. Wonder what that makes the % increase in earnings from one yr to the next - hmmm Comments?